Pegavision Corporation (6491.TW)
TWD 335.5
(-3.59%)
TWD 335.5
(-3.59%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 63.52 Million TWD | 107.66% |
| 2022 | -829.5 Million TWD | 24.47% |
| 2021 | -1.09 Billion TWD | -45.16% |
| 2020 | -756.6 Million TWD | -48.91% |
| 2019 | -508.08 Million TWD | -332.87% |
| 2018 | 218.18 Million TWD | 149.71% |
| 2017 | -438.93 Million TWD | -214.68% |
| 2016 | -139.48 Million TWD | -9.82% |
| 2015 | -127.01 Million TWD | 39.81% |
| 2014 | -211.03 Million TWD | -1235.08% |
| 2013 | 18.59 Million TWD | 108.81% |
| 2012 | -211.03 Million TWD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 23.63 Million TWD | -62.79% |
| 2024 Q3 | -382.76 Million TWD | -2835.94% |
| 2024 Q2 | 11.44 Million TWD | -51.59% |
| 2023 Q3 | -1.35 Billion TWD | -898.52% |
| 2023 Q4 | 63.52 Million TWD | 104.69% |
| 2023 Q1 | 126.55 Million TWD | 115.26% |
| 2023 FY | 63.52 Million TWD | 107.66% |
| 2023 Q2 | 169.69 Million TWD | 34.09% |
| 2022 Q4 | -829.5 Million TWD | -144.64% |
| 2022 Q1 | -1.03 Billion TWD | 5.6% |
| 2022 Q2 | -586.22 Million TWD | 43.46% |
| 2022 FY | -829.5 Million TWD | 24.47% |
| 2022 Q3 | -339.07 Million TWD | 42.16% |
| 2021 Q2 | -1.23 Billion TWD | 8.91% |
| 2021 Q1 | -1.35 Billion TWD | -79.57% |
| 2021 Q3 | -945.21 Million TWD | 23.62% |
| 2021 Q4 | -1.09 Billion TWD | -16.19% |
| 2021 FY | -1.09 Billion TWD | -45.16% |
| 2020 FY | -756.6 Million TWD | -48.91% |
| 2020 Q4 | -756.6 Million TWD | -1.05% |
| 2020 Q1 | -223.35 Million TWD | 56.04% |
| 2020 Q2 | -717.18 Million TWD | -221.1% |
| 2020 Q3 | -748.75 Million TWD | -4.4% |
| 2019 Q1 | 505.28 Million TWD | 131.59% |
| 2019 FY | -508.08 Million TWD | -332.87% |
| 2019 Q4 | -508.08 Million TWD | -147.09% |
| 2019 Q3 | 1.07 Billion TWD | -11.05% |
| 2019 Q2 | 1.21 Billion TWD | 140.05% |
| 2018 Q2 | 98.61 Million TWD | -86.25% |
| 2018 Q1 | 717.17 Million TWD | 263.39% |
| 2018 FY | 218.18 Million TWD | 149.71% |
| 2018 Q4 | 218.18 Million TWD | 0.0% |
| 2017 Q1 | -604.42 Million TWD | -333.31% |
| 2017 FY | -438.93 Million TWD | -214.68% |
| 2017 Q3 | -387.42 Million TWD | 41.5% |
| 2017 Q2 | -662.28 Million TWD | -9.57% |
| 2017 Q4 | -438.93 Million TWD | -13.29% |
| 2016 FY | -139.48 Million TWD | -9.82% |
| 2016 Q4 | -139.48 Million TWD | -65.4% |
| 2016 Q3 | -84.33 Million TWD | 47.66% |
| 2016 Q1 | -80.11 Million TWD | 36.93% |
| 2016 Q2 | -161.11 Million TWD | -101.1% |
| 2015 Q4 | -127.01 Million TWD | -253.16% |
| 2015 Q2 | -77.73 Million TWD | -495.72% |
| 2015 FY | -127.01 Million TWD | 39.81% |
| 2015 Q3 | -35.96 Million TWD | 53.73% |
| 2015 Q1 | 19.64 Million TWD | 109.31% |
| 2014 Q1 | 153.25 Million TWD | 724.33% |
| 2014 Q2 | 154.64 Million TWD | 0.9% |
| 2014 Q3 | -115.45 Million TWD | -174.66% |
| 2014 Q4 | -211.03 Million TWD | -82.79% |
| 2014 FY | -211.03 Million TWD | -1235.08% |
| 2013 Q4 | 18.59 Million TWD | -73.8% |
| 2013 Q1 | 261.19 Million TWD | 0.0% |
| 2013 FY | 18.59 Million TWD | 108.81% |
| 2013 Q3 | 70.95 Million TWD | 0.0% |
| 2012 FY | -211.03 Million TWD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Nang Kuang Pharmaceutical Co., Ltd. | 227.48 Million TWD | 72.076% |
| Maxigen Biotech Inc. | -431.03 Million TWD | 114.737% |
| SciVision Biotech Inc. | -163.18 Million TWD | 138.926% |
| Bionime Corporation | 2.42 Billion TWD | 97.381% |
| Visco Vision Inc. | 563 Million TWD | 88.717% |